obesity drug glp-1 news today weight loss drugs leave users low on key nutrients, study finds Alarming rise in weight loss

You can find previous posts in the Employer Coverage archive Please subscribe, like and suggest this newsletter to friends and colleagues

Because weight loss is already common across NDDs, excessive or rapid GLP-1RAinduced weight loss may exacerbate frailty, potentially offsetting neurological benefits

For obesity treatment in the UK, NHS-commissioned semaglutide 2.4mg (Wegovy) is limited to a maximum of 2 years through specialist weight management services, with specific BMI thresholds (including lower thresholds for some ethnic groups)

[DOI] [PubMed] [Google Scholar] 45.Buysschaert M., Baeck M., Preumont V., Marot L., Hendrickx E., Van Belle A., Dumoutier L

Subgroup analyses were performed to explore efficacy differences in receptor specificity